SCHEMBL4117315

SCHEMBL4117315

CCOC(=O)/C(=N\Cc1ccccc1)c1ccccc1CCNC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.38
ATM Q13315 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
HTT P42858 1/20 0.38
SCN2A Q99250 3/20 0.37
SCN1A P35498 2/20 0.37
SCN3A Q9NY46 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HIF1A Q16665 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117318 1.00 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4122272 0.84 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4110227 0.84 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4110223 0.84 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4122742 0.82 HIF1A (0.46) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4122746 0.82 HIF1A (0.46) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4132647 0.79 TSHR (0.45) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4130779 0.77 MPO (0.46) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4122309 0.76 TSHR (0.42) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL4110253 0.76 GAA (0.43) SMN1; SMN2MEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258302-B2 Method for producing benzazepinone API CORPORATION (JP) 2012-09-04 US disclosed
US-20090171090-A1 METHOD FOR PRODUCING BENZAZEPINONE API CORPORATION (JP) 2009-07-02 US disclosed
EP-1985615-A1 METHOD FOR PRODUCING BENZAZEPINONE API Corporation (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171090-A1 METHOD FOR PRODUCING BENZAZEPINONE NISCH, GABBR1, GABBR2 SMN1; SMN2 3973/4885MEN1 1559/4885KMT2A 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.